Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 500
- Registration Number
- NCT05579249
- Locations
- 🇺🇸
Nutrition Research Centre, Loma Linda, California, United States
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- David Sanchez Garcia
- Target Recruit Count
- 35
- Registration Number
- NCT05467514
- Locations
- 🇲🇽
Centro Médico Nacional del Noreste Hospital de Especialidades UMAE 25, Monterrey, Nuevo León, Mexico
A Study of LY3537021 in Healthy Participants
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT05444569
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05438186
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT05360147
- Locations
- 🇨🇳
The third hospital affiliated to the Third Military Medical University, Chongqing, Chongqing, China
Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-10-17
- Target Recruit Count
- 324
- Registration Number
- NCT05313529
- Locations
- 🇨🇳
Department of Endocrinology, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
🇨🇳Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
🇨🇳Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 38
- Registration Number
- NCT05268627
- Locations
- 🇪🇬
Specialized Medical Hospital,Mansoura University, Mansourah, Dakhlia, Egypt
🇪🇬MansouraU, Mansoura, Egypt
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Biolingus
- Target Recruit Count
- 15
- Registration Number
- NCT05268237
- Locations
- 🇭🇰
Clinical Trials Unit, Chinese University of Hong Kong, Hong Kong, Hong Kong
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 3474
- Registration Number
- NCT05162183
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 34
- Registration Number
- NCT04883346
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.